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Cancer therapy directed at specific, frequently occurring molecular alterations in signaling pathways of cancer cells has been
validated through the clinical development and regulatory approval of agents such as Herceptin for the treatment of advanced
breast cancer and Gleevec for chronic myelogenous leukemia and gastrointestinal stromal tumors.While most novel, target-
directed cancer drugs have pregenomic origins, one can anticipate a postgenomic wave of sophisticated “smart drugs” to
fundamentally change the treatment of all cancers. With these prospects, interest in this new class of therapeutics extends
from basic research scientists to practicing oncologists and their patients. An extension of the initial successes in molecular
oncology will occur more quickly and successfully through an appreciation of lessons learned with the first group of agents in
their progress through clinical development.
Introduction
Herceptin (trastuzumab) for the treatment of metastatic breast
cancer and Gleevec (imatinib mesylate) for the therapy of
patients with Philadelphia chromosome-positive (Ph+) chronic
myelogenous leukemia (CML) are the first examples of gene-
based cancer drugs, and represent the most significant devel-
opments toward a new era of target-directed therapies. These
agents not only prolong life and improve its quality, they also
provide clinical validation of the emerging field of molecular
oncology, specifically therapies targeting kinase enzymes that
play a critical role in tumorigenesis. The lessons learned with
Herceptin and Gleevec and with late stage development agents
directed at the tyrosine kinase activity of the epidermal growth
factor receptor (EGFR) and vascular endothelial growth factor
receptor (VEGFR2) have caused a general shift in strategy and
tactics in drug development. This article reviews those lessons
and their application in the development of other agents, target-
ing these and other kinases that have more recently entered the
development pipeline (Table 1).
HER2/neu as breast cancer target
The breakthrough discovery of Bishop and Varmus that cancer-
inducing genes of animal retroviruses such as v-src or v-ras
represent mutated host genes that were recombined into the
viral genome raised the question of whether the oncogene con-
cept was also relevant to human cancer (Varmus and Bishop,
1986). The first cloning and sequence analysis of a cDNA
encoding a cell surface protein, the human EGF receptor, pro-
vided a partial answer to this question by revealing a close rela-
tionship with the v-erbB oncogene (Downward et al., 1984;
Ullrich et al., 1984). This first connection between a human
gene product that regulates normal cell proliferation and a viral
oncogene strongly suggested that human cancer development
may also involve abnormalities in the expression and structure
of endogenous genes that have regulatory roles in cell prolifera-
tion. A search for such genetic aberrations in tumor tissues
using cDNA probes of EGFR and an accidentally cloned EGFR-
related gene, termed HER2 (human EGFR-related gene),
resulted in the discovery that the gene encoding the HER2/neu
receptor tyrosine kinase is amplified up to 100-fold in the tumor
cells of about 30% of patients with invasive breast cancer. A sig-
nificant clinical correlation was shown between HER2/neu gene
amplification and overexpression and parameters of malignan-
cy, including reduced survival and reduced time to relapse, rela-
tive to patients with normal receptor levels (Slamon et al., 1987;
Chazin et al., 1992).
These findings led to the development of Herceptin (anti-
HER2 Mab; Trastuzumab; Genentech), the first genomic
research-based, targeted anti-kinase therapeutic approved for
cancer therapy. It was designed by humanizing the mouse mon-
oclonal antibody 4D5 (Fendly et al., 1990) that binds HER2/neu
on the surface of tumor cells, thereby inducing receptor internal-
ization and inhibition of cell cycle progression through mecha-
nisms that include upregulation of p27kip1, an intracellular
inhibitor of cyclin-dependent kinase 2 (CDK2) (Carter et al.,
1992; Shepard et al., 1991; Rieske et al., 1999). In clinical trials
with patients with metastatic breast cancer, objective responses
were seen in previously treated patients (15%) with Herceptin
used alone (Cobleigh et al., 1999), and particularly encouraging
efficacy was seen with Herceptin in combination with standard
chemotherapy (Slamon et al., 2001). Demonstration of the anti-
tumor activity of Herceptin against breast cancer provided the
proof of principle for therapy targeted to receptor tyrosine kinas-
es (RTKs), a class of cell surface receptors with an intrinsic
intracellular tyrosine kinase activity that includes Her2/neu,
EGFR, IGF-1R, PDGFR, CSF-1R, c-kit, Flt 4, FGFR, Met, and
Tie-2, all of which have been identified as potential therapeutic
targets in cancer therapy (Shawver, 1999).
HER2/neu-overexpressing breast cancer cells are readily
identified by immunohistochemistry and/or fluorescence in situ
hybridization (FISH), allowing selection of patients that are like-
ly to respond to Herceptin therapy. However, since breast can-
cer and most other types of cancer are believed to be caused by
multiple genetic events, a key to success in treating these can-
cers will be found in a rational combination of agents, each of
which contributes uniquely to the elimination of cancer cells.
Breast tumors that overexpress HER2/neu are less responsive
to chemotherapy. Experimental studies have shown that
HER2/neu overexpression confers resistance to taxanes and
that Herceptin enhances the response of HER2/neu-overex-
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pressing breast cancer cells to taxanes as well as to anthracy-
clines and platinum compounds (Yu, 2001). In a phase III com-
parison trial with Herceptin added to first-line therapy with
anthracycline-cyclophosphamide or paclitaxel in patients with
HER2/neu-overexpressing metastatic breast cancer, the benefit
obtained with Herceptin was significantly greater than that
achieved with the standard therapy alone. Median survival was
significantly increased (25.1 versus 20.3 months, P = .046), with
a 20% overall improvement of survival (Slamon et al., 2001). On
the basis of these findings, Herceptin received regulatory
approval in the United States for use with paclitaxel in the first-
line treatment of patients with HER2/neu-overexpressing
metastatic breast cancer. Herceptin is also approved as a single
agent in the treatment of patients with HER2/neu-overexpress-
ing metastatic breast cancer who had received at least one prior
cycle of chemotherapy for metastatic disease. Ongoing studies
with Herceptin are extending its use in breast cancer to the
adjuvant setting and with other combination chemotherapy reg-
imens. Moreover, second-generation Herceptin therapies, such
as the cytotoxic conjugate Herceptin-DM1 and the monoclonal
antibody 2C4 (Fendly et al., 1990) have shown promise in pre-
clinical testing.
The Herceptin clinical trials were the first studies to include
patients who shared a genetic abnormality in their tumor cells
(HER2 gene amplification), and who were therefore likely to
respond to target-specific therapy.These trials also showed that
a targeted therapy may be effective as a single agent. However,
the efficacy of Herceptin and that of standard chemotherapy
may be enhanced by combination. Identification of the optimally
effective combination regimens remains an important objective
in the era of molecular therapeutics. It is likely that future cancer
therapies will involve a combination of target-specific agents
that are aimed at different hallmark characteristics of tumor
cells, such as hyperproliferation, angiogenesis, invasiveness,
and antiapoptosis, rather than traditional cytotoxic compounds.
Targeting the Bcr-Abl kinase: Gleevec (STI571; Imatinib
mesylate; Novartis)
As described in a recent review by B.J. Druker (Druker, 2002),
the p210 Bcr-Abl is a constitutively active cytoplasmic tyrosine
kinase present in virtually all patients with CML and 15% to 30%
of adult patients with acute lymphoblastic leukemia (ALL). It is a
model target for cancer therapy, because the Bcr-Abl tyrosine
kinase by itself is sufficient for the development of leukemia,
and all transforming activities of Bcr-Abl depend on this enzy-
matic activity (Daley et al., 1990; Heisterkamp et al., 1990;
Kelliher et al., 1990). Bcr-Abl is created through a reciprocal
translocation between chromosomes 9 and 22, which results in
a fusion between the genes encoding the abl tyrosine kinase
and bcr (Rowley, 1973; de Klein et al., 1982). This translocation
generates the distinctive Philadelphia chromosome, an easily
identified marker for CML. Gleevec is a low molecular weight
inhibitor of the tyrosine kinase activity of Bcr-Abl, as well as that
of Abl, PDGFR, and c-kit, the receptor for stem cell factor.
Gleevec blocks adenosine triphosphate (ATP) binding to the
kinase, preventing phosphorylation reactions required for trans-
duction of signals that stimulate cell proliferation and inhibit nor-
mal mechanisms of cell death, indefinitely extending the life of
the malignant cells. Clinical trials with Gleevec confirmed the
validity of Bcr-Abl as a target in CML. In phase II studies with
532 patients with chronic phase CML, Ph+ cells were complete-
ly cleared from the circulation of nearly all (95%) patients, all of
whom had previously failed standard interferon therapy. These
hematologic responses usually occurred within 4 weeks and
were durable, with only 9% of patients relapsed at a median fol-
lowup interval of 18 months (Druker, 2002). The regulatory
application for use of Gleevec in CML in patients in blast crisis,
accelerated phase, or in chronic phase after interferon failure
was approved within 3 months of submission.The speed of pas-
sage of this agent through clinical trials and regulatory review
has become a case study in rapid drug development.
Gleevec was most effective against CML in patients in the
early chronic phase of the disease. Among patients in myeloid
blast crisis, there were fewer responses (52%), and most (78%)
responding patients relapsed within 1 year. Relapse coincided
with point mutations in the bcr-abl kinase domain in about half
the relapsed patients, and in a third of patients, relapse could be
ascribed to bcr-abl gene amplification and kinase overexpres-
sion (Gorre et al., 2001; Hochhaus et al., 2001; Shah et al.,
2001). De novo resistance correlated with more advanced dis-
ease and was possibly related to accumulation of resistance-
conferring mutations during disease progression (Druker,
2002). In the treatment of CML with Gleevec, clinical efficacy is
highly correlated with early initiation of therapy, a lesson that will
Table 1. Tyrosine kinase targeted therapies
Common name Trade name Target Indicationa Company
Gleevec Gleevec Brc-Abl,c-kit, PDGFR CML,GIST Novartis
Herceptin Herceptin Her2/neu Breast cancer Genentech
Cetuximab Erbitux EGFR Colorectal cancer Imclone
ZD1839 Iressa EGFR NSCLC AstraZeneca
OSI-774 Tarceva EGFR Pancreatic cancer OSI/Genentech/Roche
PKI 166 NA/ND EGFR + Novartis
GW2016 NA/ND EGFR + GlaxoSmithKline
CI-1033 NA/ND EGFR + Pfizer
EKB-569 NA/ND EGFR + Wyeth
Semaxanib NA/ND VEGFR2 Colorectal cancer SUGEN/Pharmacia
ZD6474 NA/ND VEGFR2 + AsraZeneca
PTK-787 NA/ND VEGFR1, R2 + Novartis/Schering AG
INC-1C11 NA/ND VEGFR2 + ImClone
+, agents in early clinical development; CML, chronic myelogenous leukemia; EGFR, epidermal growth factor receptor; GIST, gastrointestinal stromal
tumors; NA/ND, not available/not determined; NSCLC, non-small cell lung cancer; VEGFR2, vascular endothelial growth factor 2.
aApproved indication or primary indication sought. Other potential indications are referred to in the text.
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likely apply to other types of cancer as well (Allan et al., 1995;
Druker, 2002).
The success of Gleevec in CML was extended quickly to
gastrointestinal stromal tumors (GIST) in which an activating
mutation in the gene encoding the receptor tyrosine kinase c-kit
has been identified as a pathogenic event. Remarkable clinical
activity was seen in this chemotherapy-refractory tumor, leading
to approval in 2002 for use in patients with advanced GIST
(Blanke et al., 2001; Van Oosterom et al., 2001). Activating c-kit
mutations also occur in acute myeloid leukemias (Kanakura et
al., 1993), small cell lung cancer (Hibi et al., 1991), neuroblas-
toma (Cohen et al., 1994), germ cell tumors (Strohmeyer et al.,
1991), and breast cancers (Hines et al., 1995), although it is not
known whether c-kit activation is a critical event in these tumors.
Clinical trials will determine the importance of activated c-kit in
these cancers and the significance of this activation with
respect to efficacy of treatment with Gleevec (Druker, 2002).
Targeting the epidermal growth factor receptor
The receptor for epidermal growth factor is one of 4 members of
an RTK subfamily that also includes HER2, HER3, and HER4.
The first member of this family to be sequenced and described
(Ullrich et al., 1984), the EGFR (c-erbB1), is broadly expressed
in a variety of cells of ectodermal or mesodermal origin (Borg et
al., 2000). Overexpression of EGFR commonly occurs in many
types of cancer, such as head and neck, non-small cell lung
(NSCLC), laryngeal, esophageal, gastric, pancreatic, colon,
renal cell, bladder, breast, ovarian, cervical, prostate and papil-
lary thyroid cancers, melanoma, and gliomas, and correlates
with a poor clinical outcome (Nicholson et al., 2001). Signaling
through the EGFR activates pathways that stimulate many of
the properties associated with cancer cells: proliferation, migra-
tion, stromal invasion, tumor neovascularization, and resistance
to cell death-inducing signals (Schlessinger, 2000). The princi-
pal EGFR ligands are EGF and transforming growth factor-α
(TGF-α), heparin binding EGF (HB-EGF), amphiregulin, beta-
cellulin, and epiregulin. Tremendous signaling diversity occurs
in the EGFR family through heterodimer formation among fami-
ly members and activation by various
splice forms of Heregulin ligands (Yarden
and Sliwkowski, 2001).
The first efforts to target EGFR in
cancer therapy by Mendelsohn and col-
leagues used a monoclonal antibody to
extracellular epitopes of the receptor,
and clinical evaluation of this antibody is
still underway (C225; Cetuximab)
(Kawamoto et al., 1983). In recent years,
several pharmaceutical companies have
developed small-molecule inhibitors of
EGFR tyrosine kinase activity. Several
agents are currently in clinical development, differing in their
specificity for EGFR and other members of the HER2 family,
their potency, and the reversibility of their interaction with the
ATP binding site in the kinase domain of the receptor (Table 1).
As these agents progress through clinical development, more
will be learned regarding the value of these differences in deter-
mining the overall efficacy and usefulness. Among the EGFR
inhibitors in clinical development, Iressa (ZD1839,
AstraZeneca) has progressed furthest, and its development is
influencing that of other targeted therapeutics.
Iressa, a small molecule ATP binding site inhibitor like
Gleevec, exhibits growth inhibitory effects against a wide variety
of human tumor xenografts, although tumor regrowth typically
follows termination of treatment (Ciardiello et al., 2000). Growth
inhibition is associated with cell cycle arrest mediated through
upregulation of p27Kip1(Budillon et al., 2000), the same mecha-
nism proposed for Herceptin-mediated inhibition of cell prolifer-
ation through HER2/neu (Browder et al., 2000). As with
Herceptin, Iressa enhanced the antitumor effects of taxanes
and platinum compounds in preclinical animal studies
(Ciardiello et al., 2000), but in contrast to Herceptin, the efficacy
of Iressa is apparently not directly related to the level of EGFR
expression (Albanell et al., 2001).
Iressa has progressed rapidly in a development program
that early recognized the significance of its activity in managing
patients with NSCLC, both as a single agent in patients whose
disease was refractory to other therapies and in combination
with standard regimens in the first-line setting. In single-agent
trials, partial responses, minor responses, and disease stabi-
lization were reported in about 25% of patients. Notable
responses were seen among patients with advanced NSCLC
who had received extensive prior chemotherapy (Ferry et al.,
2000; Baselga et al., 2000). Accelerated regulatory approval is
being sought for Iressa as a single agent in the treatment of
patients with metastatic NSCLC who have failed standard ther-
apy.
Identifying a clinical setting in which a new agent may pro-
vide substantial improvement over current therapy presents an
Figure 1. Semaxanib efficacy in a tumor model
C6 gliomas on day 4 after glioma cell implanta-
tion and daily treatment with saline/DMSO (50
µl/day, IP, top panels) or SU5416 (25 mg/kg/day,
IP, bottom panels) visualized by intravital
microscopy applying transillumination (right
panels) and combined trans- and epiillumina-
tion techniques (left panels). Tumor cells are
stained with Fast Blue (Sigma), allowing exact
identification of tumor mass. Reprinted with per-
mission from Vajkoczy et al. (1999).
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opportunity for accelerated regulatory approval. The rapid
progress of Iressa and Gleevec have established a new pattern
for targeted therapeutics in clinical development, which focuses
on an identified unmet clinical need and progresses from an ini-
tial phase I/II clinical trial to registration in 4 to 5 years, com-
pared with the 7 or more years required with a conventional pro-
gram of phase I/II/III development.
Breast cancer patients whose tumors express EGFR and
overexpress HER2/neu have more aggressive disease than
those with tumors that do not overexpress HER2/neu.
Therapeutic strategies directed at these particularly aggressive
breast cancers include combinations of agents specific for
EGFR and HER2/neu, as well as single agents that target the
kinase activity of both receptors. The first combination of target-
ed therapeutics to enter clinical trials is Iressa and Herceptin in
patients with metastatic breast cancer (Moulder et al., 2001).
Agents such as CI-1033 and EKB-569 that inhibit both EGFR
and HER2 may also be particularly effective against these can-
cers, although results of such trials have not been reported yet.
Targeting the VEGFR2 (KDR): Antiangiogenic therapy
Angiogenesis has been the subject of recent review articles
(Fox et al., 2001; Liekens et al., 2001). The Folkman laboratory
and, in recent years, a host of scientists and clinical investiga-
tors have established the essential nature of tumor angiogene-
sis in expansive cancer growth (Folkman, 1999). Antiangiogenic
strategies direct therapy at the developing tumor neovascula-
ture, rather than the tumor cell, and have attractive advantages,
including reduced likelihood of genetic drug resistance and
broad application among different types of cancer. More than 40
agents that principally target neovascularization are currently
under clinical investigation in over 60 clinical studies. About a
third of the molecular therapeutics in clinical development are
directed against vascular endothelial growth factor (VEGF) or
its principal receptor, the RTK VEGFR2 (KDR). Other angiogen-
esis-relevant targets include the RTKs VEGFR3, FGF recep-
tors, and Tie2 and the integrin αvβ3. VEGF, however, stands out
as the growth factor most consistently associated with angio-
genesis and with clinical outcome in a variety of malignancies
(Pinedo and Slamon, 2000). Inhibiting the function of VEGFR2
in endothelial cells is sufficient to prevent tumor growth in exper-
imental models (Millauer et al., 1994), and since VEGFR2
expression is limited to endothelial cells, the toxicity potential of
any agent specifically directed toward inhibiting VEGFR2 activi-
ty is expected to be small (Ellis et al., 2001).
Among the VEGFR2 inhibitors, Semaxanib (SU5416,
SUGEN/Pharmacia) has progressed furthest in clinical devel-
opment. The lessons learned in development of this compound
may be applicable to other antiangiogenic agents. Semaxanib
competitively blocks ATP binding to the tyrosine kinase domain
of VEGFR2, and thereby tumor angiogenesis, inhibiting the
growth of xenografts established from a variety of human can-
cers (Fong et al., 1999). Experimentally, the antiangiogenic
activity of semaxanib was demonstrated in a rat glioma model in
which tumor growth and vascularization could be monitored by
videomicroscopy (Figures 1 and 2). Semaxanib treatment of
rats with a growing tumor reduced the density and permeability
of vessels in the glioma compared with the untreated control
animals (Vajkoczy et al., 1999).
Visual demonstration of antiangiogenic activity was impor-
tant in establishing the in vivo angiogenesis inhibitory effects of
semaxanib as the mechanism of growth inhibition in the animal
model. While blocking neovascularization halts progressive
tumor growth, it does not usually cause tumor cell death or
induce the massive regressions required for an objective
response in a clinical setting, at least not with only a few weeks
of treatment. Establishing the optimum dose and regimen for
reducing the blood supply to the tumor is a clinical problem not
unique to antiangiogenesis, but one which appears to be espe-
cially critical in the development of this therapy. Efforts are being
made to address this problem through the use of imaging tech-
nologies such as dynamic contrast-enhanced magnetic reso-
nance imaging (MRI), computerized tomography (CT), positron
emission tomography (PET) scanning, and ultrasound. As yet,
these methods are not validated for reasons related to the vari-
ety of potential methods and absence of standardized protocols
(Padhani and Neeman, 2001). Nevertheless, the need to apply
these methods to measure blood flow through tumors and
assess the biologic activity of cells within the tumor is well rec-
ognized. Most current trials include an imaging component to
help demonstrate the biologic effect and provide the opportuni-
ty to improve the use of the imaging methodology.
In a pilot study with fluorouracil and leucovorin in previously
untreated patients with advanced colorectal cancer, no dose-
limiting toxicity ascribed to semaxanib was seen, objective
tumor responses were obtained, and median survival in excess
of 23 months suggested improved efficacy compared with stan-
dard fluorouracil-leucovorin therapy (Rosen et al., 2000; Miller
et al., 2001). A randomized comparison trial of the same regi-
Figure 2. Semaxanib inhibits tumor angiogenesis in tumor xenografts
C6 glioma microvasculature in animals treated with DMSO (50 µl/day, IP;
left row) or SU5416 (25 mg/kg/day, IP; right panels) on day 6 (top panels)
and 18 (middle and bottom panels) after glioma cell implantation.
Intravital multifluorescence videomicroscopy; contrast enhancement with
2% FITC-dextran150 IV. Reprinted with permission from Vajkoczy et al. (1999).
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men, however, showed no statistically significant clinical bene-
fit, although some patients showed striking responses. These
studies with semaxanib have provided useful information on tar-
geting tumor angiogenesis through the VEGF receptor. They
have also helped define the optimal use of angiogenesis
inhibitors as single agents in patients with minimal residual dis-
ease or in combination with other cancer therapies. For exam-
ple, additive and supradditive effects have been reported in pre-
clinical studies of antiangiogenic therapy combined with radia-
tion (Gorski et al., 1999; Geng et al., 2001). This is a counterin-
tuitive finding, in that a treatment reducing tumor blood flow and
consequently the oxygen tension within a tumor would be
expected to reduce, not enhance, the cytotoxic effects of radia-
tion therapy. A proposed mechanism, however, involves inhibi-
tion of a radiation-induced survival response with increased
production of VEGF by tumor cells. VEGF blocks the cytotoxic
effects of radiation on the microvascular endothelial cells of the
tumor through a mechanism involving upregulation of antiapop-
totic mechanisms (Bcl-2) in the endothelium. The efficacy of
radiation therapy with a VEGFR2 inhibitor added to the protocol
may be equal to that associated with higher radiation doses
(Kozin et al., 2001).This suggests the possibility of delivering an
effective therapeutic dose to patients unable to tolerate usually
effective, higher doses of radiation alone.
New targets and perspectives
Generated by the success of Gleevec and Herceptin, the impe-
tus for development of new targeted therapeutics that hold
some promise as targets in cancer therapy extends to RTKs
beyond HER2/neu, EGFR, and VEGFR2.The PDGF receptor is
an RTK primarily found on fibroblasts and smooth muscle cells
and also expressed in the kidney, testes, and brain. In glioblas-
toma, a large proportion of tumor cells express both PDGF and
PDGFR, creating an autocrine stimulatory loop believed to be
important early in tumor development and progression.
PDGF/PDFGR autocrine loops have also been reported in
meningioma, melanoma, neuroendocrine cancers, and cancers
of the ovary, pancreas, stomach, lung, and prostate (George,
2001; Ostman and Heldin, 2001). Among the PDGFR inhibitors,
CDP860 (Celltech) is being tested in Phase I trials, while SU101
trials were terminated in phase III due to extreme pharmacoki-
netic variation in glioblastoma patients and in spite of impres-
sive responses in some cases.
Met, the receptor for hepatocyte growth factor (HGF), is an
RTK normally expressed by adult epithelial cells during cell
migration and wound healing. Its relationship to cancer progres-
sion and metastasis has been recently reviewed (Jiang et al.,
1999; van der Vort et al., 2000). Met is expressed by cancer
cells of various origin in which both HGF and Met may be over-
expressed. Activating mutations and gene amplification in the
Met gene have been observed in some cancers.
Experimentally, expression of HGF and Met or mutant Met con-
ferred malignant properties on normal cells (motility, invasion,
tumorigenicity). Clinically, HGF/Met overexpression has been
shown to correlate with poor prognosis in several types of can-
cer (Longati et al., 2001).
In addition to the RTKs, several cytoplasmic kinases have
properties that suggest key roles in the regulation of the cell
cycle, gene transcription, motility, cell death, and metabolism.
Several kinases at critical junctures within these regulatory
pathways have been identified as potential targets of cancer
therapy. Among these critical kinases are protein kinase C in the
PI-3 kinase/AKT survival pathway; Src family kinases, Raf
kinase, and MEK in the cell proliferation pathways; and the
cyclin-dependent kinases regulating progression through the
cell cycle. Inhibitors of several of these kinases are in preclinical
or early-phase clinical development.
With the impressive results obtained with Herceptin and
Gleevec, the stage is set for more demonstrations of the power
of gene-based therapy development. After the completion of the
human genome sequence and the advent of powerful method-
ologies such as gene and tissue array analysis, in combination
with bioinformatics, an excellent basis has been generated for
the identification of genetic abnormalities in cancer cells and
the characterization of their pathophysiologic significance. One
can anticipate that the results of these studies will generate a
new wave of target-specific drugs which, due to the extensive
complexity of pathogenic alterations in the cancer cell signaling
network, will eventually be applied in specific combinations.
These combinations will be based on the individual patient’s
genetic fingerprint, including the comprehensive gene expres-
sion and mutation analysis of the tumor as well as a single-
nucleotide polymorphism profile of the patient’s chromosomal
DNA.
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